Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStarTakashi Yamamura, Benjamin Greenberg, H.-Christian von Büdingen et al.|Multiple Sclerosis and Related Disorders|2022Cited by 60
Understanding Treatment Decisions in Neuromyelitis Optica Spectrum Disorder: A Global Clinical Record Review with Patient InterviewsJu‐Hong Min, Marius Ringelstein, Marco Capobianco et al.|Neurology and Therapy|2023Cited by 10
Characterization of Disease Severity and Stability in NMOSD: A Global Clinical Record Review with Patient InterviewsMarco Capobianco, Dean M. Wingerchuk, Ju‐Hong Min et al.|Neurology and Therapy|2023Cited by 7